Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
262 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Traumatic Brain Injury - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Traumatic Brain Injury - Pipeline Review, H2 2016', provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects - The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Traumatic Brain Injury Overview 10 Therapeutics Development 11 Pipeline Products for Traumatic Brain Injury - Overview 11 Pipeline Products for Traumatic Brain Injury - Comparative Analysis 12 Traumatic Brain Injury - Therapeutics under Development by Companies 13 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 17 Traumatic Brain Injury - Pipeline Products Glance 18 Clinical Stage Products 18 Early Stage Products 19 Traumatic Brain Injury - Products under Development by Companies 20 Traumatic Brain Injury - Products under Investigation by Universities/Institutes 24 Traumatic Brain Injury - Companies Involved in Therapeutics Development 25 ALSP, Inc. 25 Amarantus Bioscience Holdings, Inc. 26 Athersys, Inc. 27 Beech Tree Labs, Inc. 28 Cognosci, Inc. 29 Euroscreen S.A. 30 Intellect Neurosciences, Inc. 31 Ischemix, Inc. 32 Karyopharm Therapeutics, Inc. 33 Kyorin Pharmaceutical Co., Ltd. 34 Levolta Pharmaceuticals, Inc. 35 Lixte Biotechnology Holdings, Inc. 36 Lpath, Inc. 37 MandalMed, Inc. 38 Mapreg S.A.S. 39 Neuralstem, Inc. 40 Neuren Pharmaceuticals Limited 41 NeuroNascent, Inc. 42 Neuronax SAS 43 NeuroVive Pharmaceutical AB 44 New World Laboratories, Inc. 45 Novogen Limited 46 NuvOx Pharma LLC 47 Omeros Corporation 48 PharmatrophiX, Inc. 49 Phylogica Limited 50 Prevacus, Inc. 51 QR Pharma, Inc. 52 RegeneRx Biopharmaceuticals, Inc. 53 Remedy Pharmaceuticals, Inc. 54 Sage Therapeutics, Inc. 55 SanBio, Inc. 56 STATegics, Inc. 57 Stemedica Cell Technologies, Inc. 58 SynZyme Technologies, LLC 59 Tetra Discovery Partners LLC 60 Thera Neuropharma Inc 61 vasopharm GmbH 62 VG Life Sciences, Inc. 63 Traumatic Brain Injury - Therapeutics Assessment 64 Assessment by Monotherapy Products 64 Assessment by Combination Products 65 Assessment by Target 66 Assessment by Mechanism of Action 69 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Drug Profiles 76 (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 76 2-DG - Drug Profile 77 ALP-496 - Drug Profile 78 AMRS-001 - Drug Profile 80 AST-001 - Drug Profile 89 AST-002 - Drug Profile 90 AVL-8168 - Drug Profile 91 BQ-A - Drug Profile 92 BTL-slo - Drug Profile 93 Cell Therapy for Traumatic Brain Injury - Drug Profile 94 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 95 CHEC-7 - Drug Profile 96 CHEC-9 - Drug Profile 97 CMX-2043 - Drug Profile 98 CNB-001 - Drug Profile 101 COG-1410 - Drug Profile 103 cyclosporine - Drug Profile 105 dexamethasone acetate + melatonin - Drug Profile 110 EPO-Variant - Drug Profile 111 ESN-502 - Drug Profile 112 ethinyl estradiol sulfonate - Drug Profile 113 EUC-001 - Drug Profile 114 felbamate - Drug Profile 115 glyburide - Drug Profile 116 HBI-002 - Drug Profile 119 HBI-137 - Drug Profile 120 HBN-1 - Drug Profile 121 HBN-2 - Drug Profile 122 HPI-201 - Drug Profile 123 HPI-363 - Drug Profile 124 ibudilast - Drug Profile 125 ICCN-100 - Drug Profile 133 JM-4 - Drug Profile 134 KPT-350 - Drug Profile 135 LB-201 - Drug Profile 137 LB-205 - Drug Profile 138 LM-22A4 - Drug Profile 139 LM11A-31BHS - Drug Profile 141 Lpathomab - Drug Profile 143 MAP-4343 - Drug Profile 146 Monoclonal Antibody for Central Nervous System - Drug Profile 147 N-acetyl cysteine amide - Drug Profile 148 ND-478 - Drug Profile 149 Neu-2000 - Drug Profile 150 neuregulin-1 - Drug Profile 152 NNI-370 - Drug Profile 153 NNZ-2591 - Drug Profile 154 NSI-189 - Drug Profile 156 NSI-566 - Drug Profile 160 NVP-019 - Drug Profile 168 NVX-428 - Drug Profile 169 NWL-53 - Drug Profile 170 NX-210 - Drug Profile 171 PF-05285401 - Drug Profile 172 Posiphen - Drug Profile 183 PRV-002 - Drug Profile 186 PYC-35 - Drug Profile 187 PYC-36 - Drug Profile 188 PYC-38 - Drug Profile 189 PYC-98 - Drug Profile 190 R-503 - Drug Profile 191 RGN-352 - Drug Profile 193 ronopterin - Drug Profile 197 SanFlow - Drug Profile 199 SB-623 - Drug Profile 200 sepranolone - Drug Profile 204 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 211 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 212 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 213 Small Molecules for Traumatic Brain Injury - Drug Profile 214 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 215 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 216 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 217 Stem Cell Therapy for Central Nervous System Disorder - Drug Profile 222 Stem Cell Therapy for CNS Disorders - Drug Profile 223 STSE-15 - Drug Profile 224 SYN-2 - Drug Profile 226 SYN-NCE - Drug Profile 227 T-094 - Drug Profile 228 TauC-3 - Drug Profile 229 UH-0113 - Drug Profile 230 UH-0213 - Drug Profile 231 VG-1177 - Drug Profile 232 VitalHeme - Drug Profile 234 VOLT-02 - Drug Profile 235 ZL-006 - Drug Profile 236 Traumatic Brain Injury - Dormant Projects 237 Traumatic Brain Injury - Discontinued Products 242 Traumatic Brain Injury - Product Development Milestones 243 Featured News & Press Releases 243 Appendix 255 Methodology 255 Coverage 255 Secondary Research 255 Primary Research 255 Expert Panel Validation 255 Contact Us 255 Disclaimer 256
List of Tables
Number of Products under Development for Traumatic Brain Injury, H2 2016 17 Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Number of Products under Development by Companies, H2 2016 (Contd..1) 20 Number of Products under Development by Companies, H2 2016 (Contd..2) 21 Number of Products under Development by Companies, H2 2016 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Development, H2 2016 25 Products under Development by Companies, H2 2016 26 Products under Development by Companies, H2 2016 (Contd..1) 27 Products under Development by Companies, H2 2016 (Contd..2) 28 Products under Development by Companies, H2 2016 (Contd..3) 29 Products under Investigation by Universities/Institutes, H2 2016 30 Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2016 31 Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 32 Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2016 33 Traumatic Brain Injury - Pipeline by Beech Tree Labs, Inc., H2 2016 34 Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2016 35 Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2016 36 Traumatic Brain Injury - Pipeline by Intellect Neurosciences, Inc., H2 2016 37 Traumatic Brain Injury - Pipeline by Ischemix, Inc., H2 2016 38 Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 39 Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 40 Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016 41 Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 42 Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2016 43 Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2016 44 Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2016 45 Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2016 46 Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2016 47 Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2016 48 Traumatic Brain Injury - Pipeline by Neuronax SAS, H2 2016 49 Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 50 Traumatic Brain Injury - Pipeline by New World Laboratories, Inc., H2 2016 51 Traumatic Brain Injury - Pipeline by Novogen Limited, H2 2016 52 Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2016 53 Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2016 54 Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2016 55 Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2016 56 Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2016 57 Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2016 58 Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59 Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016 60 Traumatic Brain Injury - Pipeline by Sage Therapeutics, Inc., H2 2016 61 Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2016 62 Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2016 63 Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 64 Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H2 2016 65 Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2016 66 Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H2 2016 67 Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2016 68 Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2016 69 Assessment by Monotherapy Products, H2 2016 70 Assessment by Combination Products, H2 2016 71 Number of Products by Stage and Target, H2 2016 73 Number of Products by Stage and Mechanism of Action, H2 2016 76 Number of Products by Stage and Route of Administration, H2 2016 79 Number of Products by Stage and Molecule Type, H2 2016 81 Traumatic Brain Injury - Dormant Projects, H2 2016 243 Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2016 244 Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2016 245 Traumatic Brain Injury - Dormant Projects (Contd..3), H2 2016 246 Traumatic Brain Injury - Dormant Projects (Contd..4), H2 2016 247 Traumatic Brain Injury - Discontinued Products, H2 2016 248
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
